98%
921
2 minutes
20
Multicomponent chemotherapy has increasingly become a strategy of great importance in clinical nonsmall cell lung cancer treatments. However, this type of combination chemotherapy has not led to synergistic drug activities. Herein, we present the codelivery of doxorubicin and oxaliplatin via supramolecular nanocapsules. Cucurbit[8]uril encapsulated the dual drugs by noncovalent interactions. The dual drug formulation significantly enhanced the overall cytotoxicity of each drug on cancer cells at a reduced dose, providing a higher degree of synergy compared to the free drug combination while mitigating the toxic effects of the dual drugs on normal organs. In our work, supramolecular nanocapsules can offer new means for building synergy into combination chemotherapy regimens.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.langmuir.5c01941 | DOI Listing |
Mol Biol Rep
September 2025
School of Arts and Sciences, Department of Natural and Applied Sciences, The American University of Iraq-Baghdad, Baghdad, Iraq.
The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.
View Article and Find Full Text PDFLasers Med Sci
September 2025
Laser Research Center of Dentistry, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Microbial contamination of absorbable collagen membranes used in guided bone regeneration (GBR) may compromise healing outcomes. This study aimed to investigate whether the minimum inhibitory concentration (MIC) of hydrogen peroxide (HO) can improve the antibacterial effect of indocyanine green (ICG)-mediated antimicrobial photodynamic therapy (PDT) on absorbable collagen membranes while reducing the need for high HO concentrations. A laboratory-based model was developed using Streptococcus sanguinis and Staphylococcus aureus.
View Article and Find Full Text PDFAm J Clin Oncol
September 2025
Servicio de Oncología Médica HM CIOCC, Hospital Universitario HM Sanchinarro, Facultad HM de Ciencias de la Salud de la Universidad Camilo José Cela, Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain.
Objectives: To evaluate the association between the KRAS mutational load and the histologic tumor response in patients with resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant treatment (NAC) with pegylated liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX).
Methods: This was a multicenter, single-arm, interventional, open-label, phase 2 trial in patients 18 years or older who had histologically or cytologically confirmed PDAC and were candidates for surgery and received neoadjuvant NALIRIFOX. The primary outcome was determination of the association between the KRAS mutational load and the histologic tumor response after chemotherapy.
Ned Tijdschr Geneeskd
September 2025
Amsterdam UMC, Nederlands Instituut voor Pigmentstoornissen (SNIP), Amsterdam.
Vitiligo is a chronic skin disease characterized by white patches caused by the destruction of melanocytes. The most well-known variant is non-segmental vitiligo, where patches are symmetrically distributed across the entire body, with alternating periods of stability and progression. The white patches arise due to an autoimmune reaction in which cytotoxic T-cells attack the melanocytes.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Pulmonary Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Background: The prognosis of small-cell lung cancer (SCLC) remains poor, particularly in patients with extensive-stage SCLC. The IMpower133 and CASPIAN trials revealed the efficacy of immune checkpoint inhibitors (ICIs) in extensive-stage SCLC patients with good performance status (PS). The aim of this study was to investigate the efficacy of ICIs in patients with poor PS.
View Article and Find Full Text PDF